Virtually Uniting The Anti-RAS Drug Development Field - From Early Discovery to Clinical Development
Via the latest data driven case studies from academic and industry pioneers, the 2nd RAS Targeted Drug Development Summit shone a spotlight on optimizing the selectivity and tolerability of anti-RAS therapies, exploring novel combination strategies and overcoming translational pharmacology challenges to set the stage for the 2nd generation of mutation-targeted RAS modulating therapies yet to come.
Key Focus Areas of the 2020 Summit Included:
Exploring how to leverage the internal structural biology of RAS mutations in order to produce effective and clinically viable therapies with discussions from D.E Shaw Research, The Johns Hopkins University School of Medicine & Hospital for Sick Children
A deep dive into RAS associated pathways in order to optimize combination therapies with insights from Novartis, Genentech & Deciphera Oncology
An evaluation of the mechanisms of action and resistance of RAS targets to accelerate target validation and clinical translation with insights from Abbvie, PhoreMost & Verastem Oncology
Adopting novel techniques to successfully target therapeutic vulnerabilities in RAS-driven cancers with lessons learnt from BeiGene, Genentech, Revolution Medicines, Oblique Therapeutics & Aro Biotherapeutics
Exploring the successes and future therapeutic potential of targeting mutation beyond G12C from within the RAS community with Revolution Medicines, Francis Crick Institute & MD Anderson Cancer Centre